Media Centre
Q1 2019 Results
AstraZeneca will announce its Q1 2019 Results at 07:00 BST on Friday 26th April 2019. You are invited to participate in a media conference webcast or conference call, hosted by CEO Pascal Soriot, starting at 08:45 BST.
Conference detailsLatest press releases
-
Lynparza approved in EU for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer
-
Positive results from Fasenra Phase II trial in hypereosinophilic syndrome published in New England Journal of Medicine
-
Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1
-
Proposed placing of new ordinary shares
-
AstraZeneca and Daiichi Sankyo enter collaboration for novel HER2-targeting antibody-drug conjugate
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
Contact us
Gonzalo Viña
Head of Global Media Relations
Rob Skelding
Director Global Media Relations
Matthew Kent
Director Global Media Relations
Rebecca Einhorn
Director Global Media Relations
Jennifer Hursit
Manager Global Media Relations
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
Lotta Sjösten
Manager Media Relations, Sweden
US Media Team
